7 patents
Utility
Compounds and Dosage Regimen for Use In the Prevention or Treatment of Chronic Inflammatory And/or Autoimmune Diseases
13 Apr 23
Manfred GRÖPPEL, Daniel Vitt, Hella Kohlhof, Andreas Mühler
Filed: 22 Nov 22
Utility
Treatment of Multiple Sclerosis comprising DHODH inhibitors
16 Feb 23
Methods of treating or ameliorating multiple sclerosis by the dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus or a pharmaceutically acceptable salt and/or a solvate, in particular a hydrate, thereof or a solvate, in particular a hydrate, of a pharmaceutically acceptable salt thereof, by administering to a human patient a therapeutically effective amount of the DHODH inhibitor, more specifically a daily dose of about 10 mg to about 45 mg.
Andreas MÜHLER, Hella KOHLHOF, Daniel VITT
Filed: 2 Aug 21
Utility
Vidofludimus for Use In the Treatment or Prevention of Viral Diseases
27 Oct 22
Manfred GRÖPPEL, Daniel VITT, Hella KOHLHOF, Andreas MÜHLER
Filed: 1 Jul 22
Utility
Vidofludimus for Use In the Treatment or Prevention of Viral Diseases
21 Oct 21
Manfred GRÖPPEL, Daniel VITT, Hella KOHLHOF, Andreas MÜHLER
Filed: 20 Apr 21
Utility
IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation
4 Mar 21
Jakob FELDING, Hella KOHLHOF, Manfred GROPPEL, Rolf Andreas MUHLER, Daniel VITT, Carine CHEVRIER, Mirko ZAJA, Stefan TASLER
Filed: 6 Sep 18
Utility
Novel calcium salt polymorphs as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents
21 Jan 21
Daniel VITT, Andreas MÜHLER, Manfred GRÖPPEL, Hella KOHLHOF
Filed: 15 Mar 19
Utility
Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases
18 Nov 20
Manfred GRÖPPEL, Daniel VITT, Hella KOHLHOF, Andreas MÜHLER
Filed: 21 Nov 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first